Alnylam Pharmaceuticals (ALNY) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zoetis (ZTS) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, losing 47.8% versus a loss of 49.1%. Over five years, ALNY leads with a +11.6% price change compared with -63.9% for ZTS. Alnylam Pharmaceuticals is the larger company by market cap ($31.13 billion vs $30.91 billion), about 1.0 times the size.
On valuation, Zoetis trades at a lower forward P/E (11.4x vs 18.7x for Alnylam Pharmaceuticals). Zoetis pays a dividend yielding 2.75%, while Alnylam Pharmaceuticals does not currently pay one. Zoetis converts more of its revenue into profit, with a net margin of 28.2% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | ZTS |
|---|---|---|
| Share price | $232.68 | $74.81 |
| Market cap | $31.13B | $30.91B |
| 1-day change | +3.63% | +2.37% |
| YTD return | -41.49% | -40.54% |
| 1-year return | -49.08% | -47.83% |
| 5-year return | +11.57% | -63.86% |
| P/E ratio (TTM) | 37.83 | 12.30 |
| Forward P/E | 18.73 | 11.43 |
| EPS (TTM) | $6.15 | $6.08 |
| Dividend yield | 0.00% | 2.75% |
| Annual dividend | $0.00 | $2.06 |
| Revenue (latest FY) | $3.71B | $9.47B |
| Revenue growth (YoY) | +65.19% | +2.28% |
| Net income (latest FY) | $313.75M | $2.67B |
| Gross margin | 81.77% | 71.84% |
| Operating margin | 13.51% | — |
| Net margin | 8.45% | 28.23% |
| 52-week high | $495.55 | $148.30 |
| 52-week low | $197.81 | $68.77 |
| Distance from 52-week high | -53.05% | -49.55% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +59.50% | +28.33% |
| Average volume | 1.77M | 5.46M |
| Shares outstanding | 133.81M | 413.22M |
| Employees | 2,500 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alnylam Pharmaceuticals trades at a higher earnings multiple (37.8x vs 12.3x trailing P/E).
- Zoetis offers a meaningfully higher dividend yield (2.75% vs 0.00%).
- Zoetis is more profitable, keeping 28.2 cents of every revenue dollar as net income versus 8.4 cents for Alnylam Pharmaceuticals.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +2.28%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
ALNY vs ZTS FAQ
Which is bigger, Alnylam Pharmaceuticals or Zoetis?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $31.13B compared with $30.91B for Zoetis (ZTS).
Which stock has performed better over the past year, ALNY or ZTS?
ZTS returned -47.83% over the past 12 months, compared with -49.08% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or ZTS?
ZTS has the lower trailing P/E at 12.3, versus 37.8 for ALNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Alnylam Pharmaceuticals or Zoetis?
Zoetis pays a dividend yielding 2.75%, while Alnylam Pharmaceuticals does not currently pay a regular dividend.
Are Alnylam Pharmaceuticals and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.